Hims & Hers Health: Investors Have a Chance to Seek Justice

Investors who bought shares of Hims & Hers Health between April 29, 2025, and June 23, 2025, have until August 25, 2025, to take part in a class action lawsuit. This deadline is crucial for those who want to recover losses from the company's alleged missteps. The legal action centers on claims that Hims & Hers and some of its leaders did not share important details with investors. This omission is said to have violated federal securities laws. The trouble started when Novo Nordisk ended its partnership with Hims on June 23, 2025. Novo Nordisk accused Hims of breaking the law by selling compounded drugs under false pretenses and using misleading marketing tactics that could endanger patients. The news hit Hims hard. On that day, the company's stock price dropped by $22. 24, which is a 34. 6% decrease, closing at $41. 98 per share. This sharp decline happened amid unusually high trading volume, showing how investors reacted to the news. Two lawsuits have been filed so far. The first is Sookdeo v. Hims & Hers Health, Inc. , and the second, Yaghsizian v. Hims & Hers Health, Inc. , extends the class period. Investors who want to lead the class action must file a petition with the court by August 25, 2025. For those affected, reaching out to Kahn Swick & Foti, LLC, could be a good move. They offer free consultations to discuss legal rights and potential recovery options. Lewis Kahn, the managing partner, can be contacted toll-free at 1-877-515-1850 or via email at lewis. kahn@ksfcounsel. com. More information can also be found on their website. This situation highlights the importance of transparency in corporate practices. When companies fail to disclose critical information, it can lead to significant financial losses for investors. It also underscores the role of legal actions in holding companies accountable for their actions.